Syntimmune syntimmune.com


Public lists: Pharma Startups (4733)

Syntimmune is advancing novel therapies based on its leading position in the biology of the neonatal Fc receptor (FcRn). FcRn is a well-validated target for IgG-mediated autoimmune diseases and represents a central common pathway that enables abnormal IgG responses. Syntimmune's lead candidate, SYNT001, is a biologic progressing through IND-enabling studies that specifically blocks the FcRn-IgG interaction and is being developed for the treatment of IgG-mediated autoimmune diseases. Syntimmune h...Show all

Syntimmune is advancing novel therapies based on its leading position in the biology of the neonatal Fc receptor (FcRn). FcRn is a well-validated target for IgG-mediated autoimmune diseases and represents a central common pathway that enables abnorma...Show all

Company (Alive / Active)

Phone: 212-498-0011 X 301

Fax:

257 Park Avenue South
15th Floor
New York, 10010
New York, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Syntimmune $76M Jun 21, 2017

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Syntimmune Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 4 investors
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)